No abstract

COVID-19 is still a deadly disease that remains yet a major challenge for humans. In recent times, many large pharmaceutical and non-pharmaceutical companies have invested a lot of time and cost in fighting this disease. In this regard, today's scientific knowledge shows that designing and producing an effective vaccine is the best possible way to diminish the disease burden and dissemination or even eradicate the disease. Due to the urgent need, many vaccines are now available earlier than scheduled. New technologies have also helped to produce much more effective vaccines, although the potential side effects must be taken into account. Thus, in this review, the types of vaccines and vaccine designs made against COVID-19, the vaccination programs, as well as the delivery methods and molecules that have been used to deliver some vaccines that need a carrier will be described.

Heterogeneity of subgenomic regions of hepatitis C virus (HCV) may be associated with response to interferon (IFN) therapy. The amino acid sequences of the PKR/eIF-2α phosphorylation homology domain (pePHD), IFN sensitivity determining region (ISDR), PKR binding domain (PKRBD), and variable region 3 (V3) were studied in 19 patients before and after 4 weeks of treatment. All patients were infected with HCV genotype 1a and were treated with pegylated-IFN and ribavirin. Thirteen patients achieved sustained viral response (responders) and six failed to clear viral RNA (nonresponders). The amino acid sequences in the pePHD and ISDR were identical in responders and nonresponders. However, amino acid substitution at position 2252 of PKRBD was significantly different between responders and nonresponders (P = 0.044). A larger number of mutations were observed in the V3 region of responders (P < 0.001). In this region, the amino acid in position 2364 differed between responders and nonresponders (responders: aspartic acid and serine, nonresponders: asparagine, P = 0.018). The amino acid sequences in the regions which were studied did not change after 4 weeks of treatment. It is concluded that the presence of specific amino acids in position 2252 of PKRBD and position 2364 of V3 might be associated with clinical response to IFN.

No abstract

Development of a green chemistry process for the synthesis of silver nanoparticles (AgNPs) has become a focus of interest. Characteristics of AgNPs were determined using techniques, such as ultraviolet-visible spectroscopy (UV-vis), Fourier transform infrared (FTIR) analysis, scanning electron microscopy (SEM), energy-dispersive X-ray spectroscopy and X-ray diffraction (XRD). The synthesised AgNPs using Thymus kotschyanus had the most growth inhibition against gram-positive bacteria such as Staphylococcus aureus and Bacillus subtilise, while the growth inhibition of AgNPs at 1000-500 µg/ml occurred against Klebsiella pneumonia and at 1000-250 µg/ml of AgNPs was observed against E. coli. The UV-vis absorption spectra confirmed the formation of the AgNPs with the characteristic peak at 415 nm and SEM micrograph acknowledged spherical particles in a nanosize range. FTIR measured the possible biomolecules that are responsible for stabilisation of AgNPs. XRD analysis exhibited the crystalline nature of AgNPs and showed face-centred cubic structure. The synthesised AgNPs revealed significant antibacterial activity against gram-positive bacteria.